NCT06046443View on ClinicalTrials.gov

A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 11, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Hypothalamic Obesity
Interventions
DRUG

LB54640

Oral daily administration

DRUG

Placebo

Placebo matched to LB54640

Trial Locations (10)

10027

Columbia University, New York

27514

The University of North Carolina at Chapel Hill, Chapel Hill

38105

St. Jude Children's Research Hospital, Memphis

52242

University of Iowa Children's Hospital, Iowa City

73112

Lynn Health Science Institute, Oklahoma City

80045

Children's Hospital Colorado, Aurora

02111

Tufts Medical Center, Boston

B15 2TG

Birmingham Women's and Children's NHS Foundation Trust, Birmingham

CB2 1TN

University of Cambridge, Cambridge

WC1N 3JH

Great Ormond Street Hospital for Children, London

All Listed Sponsors
lead

Rhythm Pharmaceuticals, Inc.

INDUSTRY

NCT06046443 - A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity | Biotech Hunter | Biotech Hunter